Effects of a specific competitive antagonist of angiotensin II on arterial pressure and adrenal steroid secretion in dogs.
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000378:metabolism*; D000311:Adrenal Glands / Q000098:blood supply / Q000187:drug effects*; D000409:Alanine / Q000494:pharmacology; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects*; D003250:Constriction; D003404:Creatinine / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology; D004285:Dogs; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D009941:Organomercury Compounds / Q000494:pharmacology; D011188:Potassium / Q000652:urine; D012083:Renin / Q000097:blood; D012521:Sarcosine / Q000494:pharmacology; D012964:Sodium / Q000652:urine; D012965:Sodium Chloride / Q000008:administration & dosage; D013329:Structure-Activity Relationship; D014682:Vena Cava, Inferior
D000305:Adrenal Cortex Hormones; D009941:Organomercury Compounds; D000804:Angiotensin II; D012965:Sodium Chloride; D000450:Aldosterone; D003907:Dexamethasone; D012964:Sodium; D003404:Creatinine; D012083:Renin; D000409:Alanine; D011188:Potassium; D006854:Hydrocortisone; D012521:Sarcosine